AstraZeneca is a global biopharmaceutical company committed to researching, developing and commercialising ethical medicines. Science is in the DNA of AstraZeneca, which has always been committed to broadening its horizons and developing drugs that significantly improve patients’ lives in many therapeutic areas: oncology, rare diseases, cardiovascular, metabolic, renal, respiratory, immunology, and infectious diseases.
Guided by science, innovation and our values, we are focused on developing therapeutic solutions that can significantly improve the lives of people suffering from a disease and society as a whole.
In Italy, AstraZeneca employs over 850 people and has invested € 26.4 million in R&D in 2021, with more than 100 clinical trials active in 500+ centres across the country.
Why MIND
AstraZeneca has joined the district and the project of MIND at 360 degrees and shares its ambitions. We want to be part of what is an ideal place to accelerate the development of ideas and a hub for innovation in Italy in the Life Sciences and Cities of the Future sector. For us, it also means playing a meaningful role in an ecosystem informed by the circular economy principles and the highest standards of environmental sustainability, providing cutting-edge solutions for people’s wellbeing.
The activities in the district
AstraZeneca is one of the founders of Federated Innovation @MIND, a collaborative model that brings together private companies and public institutions.
Among the projects developed within the model, AstraZeneca is promoting PROMETEO. The initiative provides managers, professionals and healthcare technicians with a co-design process that, starting from their needs, aims to develop innovative solutions for better managing health problems.
